We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Dental Research Effort Aims to Stem Oral Cancer in India

By LabMedica International staff writers
Posted on 23 Sep 2015
Pioneering use of laser technology to advance better methods of tracking and treating oral cancers (OCs) is leading to the ability to noninvasively detect these cancers with a portable device.

Regular biopsies were standard practice to monitor precancerous mouth lesions before they may metastasized. More...
But often patients did not return after the first biopsy due to the pain. Petra Wilder-Smith, DDS, PhD, professor-in-residence and director of the dental program at the Beckman Laser Institute & Medical Clinic, University of California, Irvine (Irvine, CA, USA) and M.A. Kuriakose, chief of head and neck oncology at the Mazumdar-Shaw Cancer Center (Bangalore, India) have partnered in leading teams to develop and test a low-cost, portable screening device that field-workers in India can use to detect possible OC. The device is solar-powered, slightly larger than a shoebox, and can take laser images of oral lesions that will be sent via mobile phone to Mazumdar-Shaw and Beckman Laser Institute for assessment. The technology could enable people—many of whom rarely see dentists—to receive early-stage care and dramatically improve their outcomes.

“Petra is widely recognized for her visionary leadership in the pioneering use of optics and photonics technologies for improving oral health,” said Bruce Tromberg, director of the Beckman Laser Institute, “She has a special combination of abilities as a compassionate clinician with a unique understanding of patient needs, particularly in medically underserved communities.”

OCs are caused by a variety of factors, including tobacco and alcohol use, HPV infections, poor diets, and the chewing of betel quid, which is common in many parts of Asia. Most OC patients first see a doctor at late stages where survival rates are under 40%. In low-resource nations like India, which has the planet’s highest burden of OC (about 80,000 new cases annually), the situation is more acute, primarily due to lack of awareness and healthcare access. Data from the Million Death Study show that OC accounts for 35% of all cancer deaths among Indian men.

The study is in its first phase. Teams from Beckman and Mazumdar-Shaw have traveled India gauging mobile phone reception, and a prototype of the device has been tested on a small group of patients. They are gearing up for testing a larger cohort of subjects across India.

“We’re in the process of reviewing the data now to figure out where we draw the lines that determine whether a measurement signifies that the tissues are normal or precancerous or malignant,” said Dr. Wilder-Smith, “We’re really satisfied with the progress.” With another collaborator at the University of Arizona, she is creating a snap-on laser device for smartphones that can also perform lesion analysis in the field. The technology is in its experimental phase, and the researchers are seeking funding to support further development. “We are truly advancing methods to remotely use laser technology to diagnose tissues, which can help out both patients and oncologists,” she said.

Related Links:

Beckman Laser Institute & Medical Clinic, U California, Irvine
Mazumdar-Shaw Cancer Center



New
Gold Member
Hematology Analyzer
Medonic M32B
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Hematology System
Medonic M16C
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.